TD Cowen Forecasts Strong Price Appreciation for Danaher (NYSE:DHR) Stock

Key Points

• TD Cowen raised Danaher’s price target to $270 from $255 and maintained a “buy” rating, implying approximately 14.8% upside from the reported share price.
• Analyst sentiment is broadly positive: Danaher has a consensus “Moderate Buy” rating and an average price target of $239.50, with multiple brokerages recently raising their targets.
• Danaher exceeded quarterly EPS expectations with $2.11 per share versus $1.92 forecast, while revenue increased 8.3% year over year to $6.55 billion; management also raised its full-year adjusted EPS outlook.

Danaher (NYSE:DHR - Get Free Report) had its target price increased by analysts at TD Cowen from $255.00 to $270.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the conglomerate's stock. TD Cowen's price target would indicate a potential upside of 14.78% from the company's current price.

DHR has been the subject of several other reports. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a research note on Monday, October 5th. Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. Morgan Stanley upped their target price on Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a research report on Monday, October 12th. Guggenheim raised their price target on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Danaher in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $239.50.

Danaher Stock Up 0.6%

Shares of Danaher stock opened at $235.23 on Thursday. The business has a 50-day moving average of $215.25 and a two-hundred day moving average of $196.84. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a market capitalization of $165.37 billion, a P/E ratio of 41.80, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher's quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the company earned $1.89 earnings per share. As a group, equities analysts predict that Danaher will post 8.53 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Prime Capital Investment Advisors LLC grew its holdings in shares of Danaher by 0.5% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate's stock valued at $2,039,000 after purchasing an additional 45 shares during the last quarter. Veery Capital LLC boosted its position in Danaher by 3.1% in the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate's stock valued at $350,000 after buying an additional 48 shares in the last quarter. Studio Investment Management LLC boosted its position in Danaher by 3.3% in the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate's stock valued at $302,000 after buying an additional 51 shares in the last quarter. OLD Second National Bank of Aurora grew its stake in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate's stock worth $2,297,000 after buying an additional 57 shares during the last quarter. Finally, Adelphi Trust Co increased its holdings in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate's stock worth $524,000 after buying an additional 57 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, well above the $1.92 consensus estimate. Revenue rose 8.3% year over year to $6.55 billion, essentially in line with expectations, while stronger Biotechnology profitability supported margin expansion. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, above the prior outlook and analyst expectations. Biotechnology orders grew at a mid-teens rate, suggesting improving customer demand and a potentially stronger recovery across key end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more constructive following the results. Stifel Nicolaus raised its price target from $220 to $260 and upgraded DHR to Buy, while Robert W. Baird lifted its target from $246 to $254 and assigned an Outperform rating. Goldman Sachs also increased its target to $275 from $250. Goldman Sachs Adjusts Price Target on Danaher
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a longer-term growth opportunity in drug discovery, while the Masimo acquisition helped offset weakness in respiratory diagnostic sales. Danaher says it has building blocks for AI drug discovery growth

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.